Australia's most trusted
source of pharma news
Monday, 17 November 2025
Posted 17 November 2025 AM
The PBAC has lifted the lid on what went wrong with MSD's attempt to win a recommendation for its multi-cancer funding proposal for Keytruda - complaining the company's submission was too complex with costing estimates unable to be verified.
MSD proposed a single weighted, effective approved ex-manufacturer price for Keytruda based on existing listed indications. A price volume arrangement (PVA) was proposed with increasing rebate levels over four tiers.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.